Racial and ethnic disparities in hematologic malignancies

Kirtane, Kedar; Lee, Stephanie J.

doi:10.1182/blood-2017-04-778225

Cited by 120 publications

(133 citation statements)

References 48 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…In an analysis of more than 37,000 MM patients, Hispanic patients had a significantly worse median overall survival compared with non‐Hispanic white patients (NHWs; 2.4 vs. 2.6 years; p < .006). Asian patients and NHBs did not have significantly different median overall survivals compared with NHWs . In addition to variation in incidence and mortality by race and ethnicity, MM is predominantly a disease of elderly patients, with an average age of diagnosis of 69 years .…”

Section: Introductionmentioning

confidence: 83%

Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

et al. 2018

View full text Add to dashboard Cite

Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, < .0001) and Hispanic patients (EF 0.04%, < .0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients.

show abstract

Section: Introductionmentioning

confidence: 83%

Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In this issue of Blood, Choi et al demonstrated an oncogenic role of RUNX1 in T-cell acute lymphoblastic leukemia (T-ALL), 1 which is in marked contrast to its tumor-suppressive role identified earlier in T-ALL, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). R UNX1 is one of the best-characterized hematopoietic transcription factors.…”

mentioning

confidence: 83%

“…1 The authors tested their hypothesis by generating a T-ALL mouse model in which the Runx1 gene was conditionally deleted. They first isolated leukemic cells from the Tal1/Lmo2 doubletransgenic mice and transplanted them into recipient mice, followed by tamoxifen treatment to delete Runx1.…”

mentioning

confidence: 99%

Racial/ethnic disparities: need more work!

Landgren

2017

Blood

View full text Add to dashboard Cite

“…The prognostic impact of race in OS is controversial. Racial disparities in outcomes may be related with biologic factors, individual factors, health behaviors, and structural barriers [60]. In a large study from the Surveillance, Epidemiology, and End Results (SEER), with more than 40,000 patients, the differences in OS between patients in the white and black race did not reach statistically significant differences [61].…”

Section: Racementioning

confidence: 99%

Epidemiology of Multiple Myeloma

Ríos-Tamayo¹,

Rodríguez²,

Chan³

et al. 2019

Update on Multiple Myeloma

View full text Add to dashboard Cite

Multiple myeloma is a heterogeneous hematological malignancy in which epidemiology plays an increasingly important role. In recent years, an unprecedented intensive research, including both clinical and molecular epidemiology, has deepened the knowledge about its pathogenesis, risk factors, and prognostic factors, leading also to the approval of new drugs. Although the etiology remains largely unknown, among the confirmed risk factors, only obesity and the exposure to certain carcinogens are potentially preventable. Familial myeloma and occupational myeloma are topics of great interest. Most population-based cancer registries show a stable incidence or only a slight trend to increase. The diagnostic delay should be avoided as much as possible. Mortality rates, including early mortality, are progressively decreasing, although infection remains the leading cause of mortality. The outcome in terms of overall survival and health-related quality of life has remarkably improved, joining the group of potentially curable malignancies. Nowadays the clinical scenario is challenging. Clinical and epidemiological variables of interest should be standardized in clinical records. Patients should be included in a population-based registry network. The clinical coordination of a multidisciplinary team in a specialized unit is needed in order to maximize the outcome of every patient.

show abstract

Racial and ethnic disparities in hematologic malignancies

Cited by 120 publications

References 48 publications

Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials

Racial/ethnic disparities: need more work!

Epidemiology of Multiple Myeloma

Contact Info

Product

Resources

About